These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34969349)

  • 1. Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis.
    Hung HY; Hung WL; Shih CL; Chen CY
    Ann Med; 2022 Dec; 54(1):108-120. PubMed ID: 34969349
    [No Abstract]   [Full Text] [Related]  

  • 2. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
    Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
    Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
    Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
    J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
    Forns X; Feld JJ; Dylla DE; Pol S; Chayama K; Hou J; Heo J; Lampertico P; Brown A; Bondin M; Tatsch F; Burroughs M; Marcinak J; Zhang Z; Emmett A; Gordon SC; Jacobson IM
    Adv Ther; 2021 Jun; 38(6):3409-3426. PubMed ID: 34021887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
    Ruwayni AA; AlObary EE; Alyahya KM
    Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
    J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
    Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
    Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
    Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
    Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.
    Wedemeyer H; Erren P; Naumann U; Rieke A; Stoehr A; Zimmermann T; Lohmann K; König B; Mauss S
    Liver Int; 2021 May; 41(5):949-955. PubMed ID: 33592123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis.
    Lu M; Rupp LB; Melkonian C; Trudeau S; Daida YG; Schmidt MA; Gordon SC
    Adv Ther; 2024 Feb; 41(2):744-758. PubMed ID: 38169058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
    Hubbard H; Lawitz E
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
    Cornberg M; Ahumada A; Aghemo A; Andreoni M; Bhagat A; Butrymowicz I; Carmiel M; Chodick G; Conway B; Song Y; Gasbarrini A; Hüppe D; Plaza FJ; Lampertico P; Alonso MLM; Myles L; Persico M; Ramji A; Sarrazin C; Villa E; Weil C; Otano JIU;
    Adv Ther; 2022 Jul; 39(7):3146-3158. PubMed ID: 35543964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
    Lawitz E; Flisiak R; Abunimeh M; Sise ME; Park JY; Kaskas M; Bruchfeld A; Wörns MA; Aglitti A; Zamor PJ; Xue Z; Schnell G; Jalundhwala YJ; Porcalla A; Mensa FJ; Persico M
    Liver Int; 2020 May; 40(5):1032-1041. PubMed ID: 31821716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.